Source:http://linkedlifedata.com/resource/pubmed/id/19282616
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2009-3-13
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0015-5691
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
133
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
139-43
|
pubmed:dateRevised |
2011-7-27
|
pubmed:meshHeading |
pubmed-meshheading:19282616-Animals,
pubmed-meshheading:19282616-Drug Delivery Systems,
pubmed-meshheading:19282616-Humans,
pubmed-meshheading:19282616-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:19282616-Nanotechnology,
pubmed-meshheading:19282616-Neovascularization, Physiologic,
pubmed-meshheading:19282616-Vascular Diseases
|
pubmed:year |
2009
|
pubmed:articleTitle |
[Therapeutic neovascularization by nanotechnology-mediated drug delivery system].
|
pubmed:publicationType |
Journal Article
|